

**August 2, 2025**

BSE Limited  
Department of Corporate Services  
Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001  
**Scrip Code No: 542665**

National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400 051  
**Company Symbol: NEOGEN**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on Saturday August 2, 2025.**

**Ref.: Regulation 30 with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).**

With reference to the captioned subject and pursuant to Regulation 33 and Regulation 30 read with Schedule III of the Listing Regulations, we wish to inform you that the Board of Directors of Neogen Chemicals Limited (“**the Company**”) had at its meeting held today i.e., Saturday August 2, 2025, at 02:30 p.m. and concluded at 5.30 p.m., inter alia considered and approved the following:

1. Approval of Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2025, pursuant to Regulation 33 of the Listing Regulations along with the “Limited Review Report” thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith as **Annexure 1**;
2. Approval of Directors’ Report with annexures, Management Discussion and Analysis Report, Business Responsibility and Sustainability Report and Corporate Governance Report for the financial year 2024-25 and Notice convening 36<sup>th</sup> Annual General Meeting (“**AGM**”) of the Company;
3. Approval of the Board for convening the 36<sup>th</sup> AGM of the Company which will be held on Friday, September 26, 2025, at 5.00 p.m. IST through video conferencing and Other Audio-Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India;
4. Approval of Record date/Cutoff Date pursuant to Regulation 42 of Listing Regulations, as Friday, September 19, 2025, for deciding eligibility of members for remote e-voting and final dividend for the financial year 2024-25 and the Register of Members and Share Transfer Register will remain closed from Saturday, September 20, 2025 to Friday, September 26, 2025 (both days inclusive) for the purpose of ascertaining the eligible members who shall be entitled to receive the dividend, if approved by the members at the 36<sup>th</sup> AGM of the Company;
5. Approval of the request of Mr. Haridas Kanani seeking retirement from and relinquishment of the position of Chairman and Managing Director with effect from end of working hours of September 30, 2025, and the Board also appreciated the huge contribution made by Mr. Haridas Kanani since the foundation of Neogen and the leadership provided by him in making Neogen a leading company in the area of Specialty Chemicals. Considering this huge contribution and the pivotal role played by him in establishing Company’s strong foundation, driving sustained growth, and fostering a culture of excellence, integrity, and innovation, and in recognition of his visionary leadership, dedication, and outstanding contributions to the Company’s progress, the Board has requested and recommended Mr. Haridas Kanani to continue in providing his guidance and mentorship to the Company and be conferred with the honorary title of “**Chairman Emeritus**” post his retirement w. e. f. October 1, 2025. The same was accepted by Mr. Haridas Kanani. The Board approved the conferring of the title “Chairman Emeritus” to Mr. Haridas Kanani w. e. f. October 1, 2025.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (as amended) ("**SEBI Circulars**"), is enclosed herewith as **Annexure 2**.

6. Granting of additional Corporate Guarantee in connection with the facilities availed by Wholly Owned Subsidiary - Neogen Ionics Limited ("**WOS- NIL**") up to Rs. 125 Crores. The details required under Regulation 30 of the Listing Regulations and SEBI circulars are enclosed herewith as **Annexure 3**.
7. On recommendation of and in consultation with the Nomination and Remuneration Committee, the Board of Directors of the Company, has approved the following:
  - (i) Re-appointment of Mr. Shyamsunder Upadhyay (DIN: 07274873) as a Whole Time Director for a further term of 3 consecutive years commencing from October 1, 2025 to September 30, 2028 (both days inclusive), liable to retire by rotation, as per the provisions of Section 203 of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations, subject to approval of the shareholders of the Company by way of Special Resolution pursuant to First Proviso of Section 196(3)(a) of the Companies Act, 2013; and
  - (ii) In light of Mr. Haridas Kanani's retirement as the Chairman and Managing Director, Board has approved designation of Mr. Anurag Surana (DIN No.: 00006665), existing Non-Executive and Non-Independent Director as a Chairman and Non-Executive and Non-Independent Director with effect from October 1, 2025, of the Company, liable to retire by rotation; and
  - (iii) Recommendation for appointment of Mr. Triplicane Commandoor Narasimhan Saikrishnan (DIN: 10498119) as an Executive Director of the Company for a term of 5 consecutive years commencing from October 1, 2025, to September 30, 2030 (both days inclusive), liable to retire by rotation, pursuant to to Section 152(2) and other applicable provisions of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations, subject to approval of the shareholders at the ensuing Annual General Meeting.

As required under Regulation 30 of the Listing Regulations read with Schedule III of the Listing Regulations and SEBI Circulars, a brief profile of Mr. Shyamsunder Upadhyay, Mr. Anurag Surana and Mr. Triplicane Commandoor Narasimhan Saikrishnan has been enclosed herewith as **Annexure-4, Annexure-5 and Annexure-6** respectively.

Further, we confirm that Mr. Shyamsunder Upadhyay, Mr. Anurag Surana and Mr. Triplicane Commandoor Narasimhan Saikrishnan are not debarred from holding the office of Director by virtue of any SEBI order or any other authority.

8. Approved the reconstitution of the following Committees of the Board of Directors w.e.f. October 1, 2025:

**A. Risk Management Committee:**

1. Mr. Anurag Surana - Non- Executive Non-Independent Director – Chairman
2. Dr. Harin Kanani – Managing Director – Member
3. Mr. Rajeshkumar Shah - Non-Executive- Independent Director – Member
4. Mr. Gopikrishnan Sarathy – CFO – Member

**B. Corporate Social Responsibility Committee:**

1. Dr. Harin Kanani - Managing Director - Chairman
2. Mr. Avi Sabavala - Independent Director – Member
3. Mr. Anurag Surana - Non- Executive Non-Independent Director – Member

**C. Nomination and Remuneration Committee:**

1. Mr. Manojkumar Pati – Independent Director – Chairman
2. Prof. Ranjan Kumar Malik – Independent Director – Member
3. Mr. Anurag Surana – Non Executive Non Independent Director – Member
4. Mr. Rajeshkumar Shah - Independent Director – Member

The above information is also being uploaded on the Company's website at <https://neogenchem.com/financial-performance/> , <https://neogenchem.com/announcements/> and at the website of the NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)).

Kindly take the above information on your records.

Yours faithfully,  
For **Neogen Chemicals Limited**

---

**Unnati Kanani**  
**Company Secretary & Compliance Officer**  
**Membership No:** ACS 35131  
**Place:** Thane  
**Encl.:** As above



FoF 2, Phoenix House, 'B' Wing,  
4th Floor, 462, Senapati Bapat Marg,  
Lower Parel,  
Mumbai-400 013.  
India

Phone : +91 22 4619 7023/24/25  
          : +91 22 4606 7023  
Email : mail@cnj.in  
Web : www.cnj.in

**Independent Auditors' Limited Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To

The Board of Directors of  
Neogen Chemicals Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Neogen Chemicals Limited ("the Company") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in Paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



## Chandabhoy & Jassoobhoy

Chartered Accountants

### 5. Emphasis of Matter

We draw attention to Note 3 to the Statement with regard to incident of Fire at Dahej SEZ Plant of the Company. This incident led to damage of certain property, plant and equipment, inventory and it also interrupted business. The Company intimated the insurance company about the fire incident and submitted loss estimate to the Insurance Company in terms of its insurance policy. The Company had appointed Independent Surveyor for ascertaining the Loss caused by Fire and the claim that the Company is entitled from the Insurance Company vis-a-vis its insurance policy. The company simultaneously had appointed Independent expert seeking opinion on accounting treatment for the Loss caused and the Claim made to the Insurance Company. Based on the Independent Surveyor's Report and Independent expert opinion:

- (i) the Company had recognised Loss caused by fire as Rs 348.16 crores and Insurance Claim receivable from Insurance Company as Rs. 334.60 crores during the previous quarter ended March 31, 2025; and
- (ii) the aforementioned losses of Rs.348.16 crores and corresponding insurance claim credit of Rs 334.60 crores has been presented on a net basis of Rs 13.56 crores under "Exceptional Items" in the standalone financial results for the previous quarter and year ended March 31, 2025.

The assessment of the loss claim submitted to the insurance company is in process. The Company has received Rs.50 crores during the quarter ended June 30, 2025 and Rs.30 crores subsequent to the quarter ended June 30, 2025 as on account payment from the insurance company.

Our opinion is not modified in respect of this matter.

6. We draw your attention to Note 2 to the Statement in respect of Scheme of Amalgamation of Buli Chemicals-India Private Limited, the wholly owned subsidiary with the Company with effect from the appointed date of April 1, 2024 as approved by the Hon'ble National Company Law Tribunal, (Mumbai Bench) vide their order dated January 9, 2025. This Scheme, being a common control transaction has been accounted for based on the pooling of interest method in the Statement in accordance with the accounting treatment specified in the Scheme, i.e. as prescribed in 'Appendix C' of Ind AS 103- "Business Combinations". Accordingly, figures included in these financial results in respect of prior period i.e. for the quarter ended June 30, 2024 have been restated as if the business combination had occurred with effect from the beginning of the previous year i.e. April 1, 2023.

Our conclusion is not modified in respect of this matter.

### 7. Other Matters

- a. The statement includes comparative figures of the Company for quarter ended June 30, 2024 which have been restated as mentioned in para 6 above based on the figures of the said periods which have been reviewed by the predecessor firm of statutory auditors who have expressed unmodified conclusion vide their report dated August 07, 2024 whose report has been furnished to us and which have been relied upon by us for the purpose of our review of the statement.

Our conclusion on the Statement is not modified in respect of this matter.





## **Chandabhoy & Jassoobhoy**

**Chartered Accountants**

---

- b. The statement includes the comparative figures of the Company for quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of the previous financial year which were subject to limited review by us.

For **Chandabhoy & Jassoobhoy**  
**Chartered Accountants**  
**Firm Registration No. 101647W**



**Bhupendra T. Nagda**  
**Partner**  
**Membership No.: 102580**  
**UDIN: 25102580BMNYZS5917**



Mumbai: August 2, 2025



**NEOGEN**  
CHEMICALS LTD.

**NEOGEN CHEMICALS LTD.**  
(CIN: L24200MH1989PLC050919)

**Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2025**

Sr. No.	Particulars	Standalone			
		For the Quarter Ended			For the year ended
		30 June 2025	31 Mar 2025	^ 30 June 2024	31 Mar 2025
		Unaudited	Audited	Unaudited	Audited
<b>I</b>	<b>Income</b>				
	(a) Revenue from operations	184.58	203.75	176.34	773.65
	(b) Other income	3.31	2.65	2.81	9.76
	<b>Total Income (net)</b>	<b>187.89</b>	<b>206.40</b>	<b>179.15</b>	<b>783.41</b>
<b>II</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	127.41	158.63	98.20	498.84
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(26.11)	(49.99)	(3.47)	(76.32)
	(c) Employee benefits expense	17.22	16.13	14.32	58.29
	(d) Finance costs	14.03	16.50	9.51	51.38
	(e) Depreciation and Amortization Expense	4.88	6.01	6.39	25.59
	(f) Other Expenses	31.38	37.81	35.47	145.71
	<b>Total Expenses</b>	<b>168.81</b>	<b>185.09</b>	<b>160.42</b>	<b>703.49</b>
<b>III</b>	<b>Profit/(loss) before exceptional item and taxes (I - II)</b>	<b>19.08</b>	<b>21.31</b>	<b>18.73</b>	<b>79.92</b>
<b>IV</b>	Exceptional items (Refer note 3)	-	13.56	-	13.56
<b>V</b>	<b>Profit/(loss) before tax (III-IV)</b>	<b>19.08</b>	<b>7.75</b>	<b>18.73</b>	<b>66.36</b>
<b>VI</b>	<b>Income Tax</b>				
	1. Prior year tax adjustment		0.16	-	0.62
	2. Current Tax	4.86	7.13	3.63	19.77
	3. Deferred Tax	(0.01)	(4.73)	1.16	(2.44)
<b>VII</b>	<b>Profit for the period (V-VI)</b>	<b>14.23</b>	<b>5.19</b>	<b>13.94</b>	<b>48.41</b>
<b>VIII</b>	<b>Other comprehensive income</b>				
	(i) Items that will not be reclassified to profit or loss	(0.12)	(0.02)	(0.20)	(0.49)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.03	0.00	0.06	0.12
	<b>Total Other comprehensive (expense)/ income, net of tax</b>	<b>(0.09)</b>	<b>(0.02)</b>	<b>(0.14)</b>	<b>(0.37)</b>
<b>IX</b>	<b>Total Comprehensive income for the period (VII+VIII)</b>	<b>14.14</b>	<b>5.17</b>	<b>13.80</b>	<b>48.04</b>
<b>X</b>	Paid up equity Share Capital (Face Value per share of Rs. 10 each)	26.38	26.38	26.38	26.38
<b>XI</b>	Other Equity		-	-	782.47
<b>XII</b>	Earning Per Equity Share Rs. (a) Basic & Diluted (*Not Annualized)	5.40*	1.97*	5.28*	18.35

Place : Thane , India  
Date : August 02,2025



For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Dr. Harin Kanani  
Managing Director  
DIN : 05136947

1. The above unaudited standalone financial results of the Company for the quarter ended June 30, 2025 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended and are in compliance with the presentation and disclosure requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and the other accounting principles generally accepted in India and were reviewed by the Statutory Auditor and recommended by the Audit Committee in its meeting held on August 2, 2025 and was approved by the Board of Directors at their meeting held on August 02, 2025.
2. ^ The Hon'ble National Company Law Tribunal, Mumbai Bench ("Hon'ble NCLT") has on January 9, 2025, pronounced the order sanctioning and approving the Scheme of Amalgamation of Buli Chemicals India Private Limited i.e. wholly owned subsidiary ("Transferor Company/BULI") with Neogen Chemical Limited i.e. holding company ("Transferee Company/ NCL/ the Company") and their respective shareholders ("Scheme"), under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder("Act") ("Order") with appointed date as April 1, 2024. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025 ("Effective Date").

The Scheme sanctioned by Hon'ble NCLT, being a common control transaction has been accounted for based on the pooling of interests method retrospectively for all periods presented in the standalone results in accordance with Appendix C to Ind AS 103 - "Business Combinations".

Accordingly, the financial information included in these financial results in respect of prior periods has been restated as if the business combination had occurred with effect from the beginning of the previous year i.e., April 1, 2023. The effect of mergers on the amounts of Revenue, Expense, Profit and Total Comprehensive Income and earning per share (EPS) published in the respective period are as shown in the below table:

(₹ in Cr)

Particulars	Quarter ended 30/06/2024
<b>Total Income</b>	
As published in respective period	166.71
As restated for the effect of the merger(s)	179.15
<b>Total Expenses</b>	
As published in respective period	153.01
As restated for the effect of the merger(s)	160.42
<b>Profit before tax:</b>	
As published in respective period	16.62
As restated for the effect of the merger(s)	18.73
<b>Profit after tax:</b>	
As published in respective period	12.42
As restated for the effect of the merger(s)	13.94
<b>Total Other comprehensive Income</b>	
As published in respective period	(0.13)





As restated for the effect of the merger(s)	(0.14)
<b>Total Comprehensive Income:</b>	
As published in respective period	12.29
As restated for the effect of the merger(s)	13.80
<b>Earning Per Equity Share Basic &amp; Diluted (*Not Annualized)</b>	
As published in respective period (In Rs)	4.71*
As restated for the effect of the merger(s) (In Rs)	5.28*

3. On March 05, 2025 there was fire at Multi-Purpose Plant (MPP3)- Facility, Tank Farms and warehouse at Dahej SEZ Plant of the Company. This incident led to damage of certain property, plant and equipment, inventory and interrupted business. The Company is adequately insured for reinstatement value of damaged fixed assets, inventory and loss of profits due to business interruption. The Company has intimated the fire incident with the insurance company and submitted loss estimate pertaining to replacement value of the damaged property, plant and equipment, loss of damaged inventory and incidental expenses incurred on account of fire. The Claim is admitted by the insurance company.

During the financial year and quarter ended March 2025, the Company has recognised loss of Rs 348.16 Crores on account of damage to certain property, plant & equipment, inventory and estimated cost of incidental charges. The Company has recognised insurance claim receivable of Rs 334.60 Crores to the extent of recovery of loss after adjusting applicable deductibility considering its assessment of loss and admissibility of claims as per the policy, adequacy of coverage and nature of loss and based upon the independent opinion obtained by the company from Independent Surveyor and Independent Expert Practitioner. The Company has not accounted claim for loss of profit due to business interruption and excess value of reinstatement of assets over-written down value as per accounting conservatism. The aforementioned losses and corresponding insurance claim has been presented on a net basis of Rs 13.56 Cr under exceptional item in standalone financial results for the previous quarter and year ended March 31, 2025.

During the quarter ended 30 June 2025, Company has received Rs 50.55 Crores (including Rs 50 Crores as on account payment from insurance company).

Subsequent to the quarter ended 30 June 2025, the Company has received additional Rs 30 Crores as on account payment from Insurance company, accordingly net claim receivable as on date reduced to Rs 254.06 Crores.

4. On April 1, 2025, the Nomination and Remuneration Committee (NRC) of the Company has approved grant of 36,400 Employee Stock Options (ESOPs) to the total of 41 eligible employees of the Company and its Subsidiary Company(ies), in India or outside India, under Neogen Chemicals Limited Employees Stock Option Scheme 2024 (Tranche – I Grant”) at an Exercise Price for the Tranche - I Grant of Options shall be Rs. 1,389/- per Option (being granted at a discount of 10% of the Market Price (rounded off) i.e. closing price of previous trading day from grant day) as approved by the NRC of the Company. For more details visit <https://neogenchem.com/wp-content/uploads/NRCOutcome.pdf>

5. The Board of Directors of the Company had in its meeting held on March 25, 2025 approved Investment in Neogen Chemicals Japan Corporation Limited (“NCL Japan”)- Wholly Owned Subsidiary of the Company upto an amount of JPY 2,00,00,000 by way subscribing to the equity shares as may be issued, offered and allotted by NCL Japan constituting 100% shareholding in NCL Japan and accordingly the Company has invested an amount of JPY



2,00,00,000 (equivalent INR 1,19,38,000) in NCL Japan. Further details in this respect can be accessed at <https://neogenchem.com/wp-content/uploads/BMoutcomee.pdf>  
[https://neogenchem.com/wp-content/uploads/update\\_ncljapan.pdf](https://neogenchem.com/wp-content/uploads/update_ncljapan.pdf) and  
[https://neogenchem.com/wp-content/uploads/Update\\_on\\_Japan\\_Investment01072025.pdf](https://neogenchem.com/wp-content/uploads/Update_on_Japan_Investment01072025.pdf).

6. The Board of Directors of Neogen Ionics Limited ("NIL") had in its meeting held on May 17, 2025, approved incorporation of NIL's Wholly Owned Subsidiary ("WOS") with the name Neogen Morita New Materials Limited ("NMNML"), which was incorporated on July 30, 2025. Accordingly, NMNML is a step down subsidiary of the Company. For more details visit:  
[https://neogenchem.com/wp-content/uploads/Reg\\_30\\_Incorporation\\_of\\_NMNML\\_clean.pdf](https://neogenchem.com/wp-content/uploads/Reg_30_Incorporation_of_NMNML_clean.pdf)
7. The Board of Directors of the Company has in its meeting held on July 12, 2025 approved the raising of funds upto Rs. 200 crores (Rupees Two hundred crores only) by issuance of fully paid, secured, listed, rated, redeemable, rupee denominated, non-cumulative, non-convertible debentures, in one or more tranches, on private placement basis. For more details visit:  
<https://neogenchem.com/wp-content/uploads/outcome-bm-july-2025.pdf>.
8. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable with the current period's classification.
9. The figures for the quarter ended March 31, 2025 is arrived at as difference between the audited figures in respect of the full financial year and the unaudited figures up to nine months period ended December 31, 2024 which were subjected to limited review.
10. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.



For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Dr. Harin Kanani  
Managing Director  
DIN : 05136947

Place : Thane , India  
Date : August 02,2025





FoF 2, Phoenix House, 'B' Wing,  
4th Floor, 462, Senapati Bapat Marg,  
Lower Parel,  
Mumbai-400 013.  
India

Phone : +91 22 4619 7023/24/25  
          : +91 22 4606 7023  
Email : mail@cnj.in  
Web : www.cnj.in

**Independent Auditors' Limited Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors of  
Neogen Chemicals Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Neogen Chemicals Limited ("the Parent") and its two subsidiaries and one joint venture (the Parent and its subsidiaries and joint venture together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standards on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



4. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review report of the other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**5. Emphasis of Matter**

We draw attention to Note 4 to the Statement with regard to incident of Fire at Dahej SEZ Plant of the Company. This incident led to damage of certain property, plant and equipment, inventory and it also interrupted business. The Company intimated the insurance company about the fire incident and submitted loss estimate to the Insurance Company in terms of its insurance policy. The Company had appointed Independent Surveyor for ascertaining the Loss caused by Fire and the claim that the Company is entitled from the Insurance Company vis-a-vis its insurance policy. The company simultaneously had appointed Independent expert seeking opinion on accounting treatment for the Loss caused and the Claim made to the Insurance Company. Based on the Independent Surveyor's Report and Independent expert opinion:

- (i) the Group had recognised Loss caused by fire as Rs 362.90 crores and Insurance Claim receivable from Insurance Company as Rs. 348.82 crores during the previous quarter ended March 31, 2025; and
- (ii) the aforementioned losses of Rs.362.90 crores and corresponding insurance claim credit of Rs 348.82 crores has been presented on a net basis of Rs 14.08 crores under "Exceptional Items" in the consolidated financial results for the previous quarter and year ended March 31, 2025.

The assessment of the loss claim submitted to the insurance company is in process. The Company has received Rs.50 crores during the quarter ended June 30, 2025 and Rs.30 crores subsequent to the quarter ended June 30, 2025 as on account payment from the insurance company.

Our opinion is not modified in respect of this matter.

6. We draw your attention to Note 2 to the Statement in respect of Scheme of Amalgamation of Buli Chemicals India Private Limited, the wholly owned subsidiary with the Company with effect from the appointed date of April 1, 2024 as approved by the Hon'ble National Company Law Tribunal, (Mumbai Bench) vide their order dated January 9, 2025. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025. Our conclusion is not modified in respect of this matter.

7. The Statement includes the results of the following entities:

Sr. no.	Name of the Entity	Relationship
1.	Neogen Chemicals Limited	Parent
2.	Neogen Ionics Limited	Subsidiary
3.	Neogen Chemicals Japan Corporation Limited	Subsidiary
4.	Dhara Fine Chem Industries (Registered Partnership Firm)	Joint Venture



**8. Other Matters**

- a. The statement includes comparative figures of the Company for quarter ended June 30, 2024 which have been reviewed by the predecessor firm of statutory auditors who have expressed unmodified conclusion vide their report dated August 07, 2024 whose report has been furnished to us and which have been relied upon by us for the purpose of our review of the statement.  
Our conclusion on the Statement is not modified in respect of this matter.
- b. We did not review the financial results of the one subsidiary included in the statement whose financial information reflects total revenues of Rs.5.43 crores, total net Profit/(loss) after tax of Rs. (3.97) crore and total comprehensive income/(expense) of Rs.(3.99) crore for the quarter ended on June 30, 2025, as considered in the statement. These financial results have been reviewed by other auditor whose review report has been furnished to us by the management and our conclusion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.  
Our conclusion on the Statement is not modified in respect of this matter.
- c. The Statement includes the interim financial information/ financial results of one subsidiary which have not been reviewed, whose interim financial information/ financial results reflects total revenues of Rs. 0.38 crore, total net profit after tax of Rs. 0.03 crore and total comprehensive income of Rs. 0.03 crore, for the quarter ended on June 30, 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 0.05 crore and total comprehensive income of Rs. 0.05 crore, for the quarter ended June 30, 2025, as considered in the Statement, in respect of 1 joint venture, based on their interim financial information/ financial results furnished to us by the management which have not been reviewed. According to the information and explanations given to us by the management, these interim financial information/ financial results are not material to the Group.  
Our conclusion on the Statement is not modified in respect of this matter.
- d. The statement includes the comparative figures of the Company for quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of the previous financial year which were subject to limited review by us.

For **Chandabhoy & Jassoobhoy**  
**Chartered Accountants**  
**Firm Registration No. 101647W**



**Bhupendra T. Nagda**  
**Partner**  
**Membership No.: 102580**  
**UDIN: 25102580BMNYZT5896**



Mumbai: August 2, 2025





**NEOGEN**  
CHEMICALS LTD.

**NEOGEN CHEMICALS LTD.**  
(CIN: L24200MH1989PLC050919)

**Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2025**

Sr. No.	Particulars	Consolidated			
		For the Quarter Ended			For the Year ended
		30 Jun 2025	31 Mar 2025	30 Jun 2024	31 Mar 2025
		Unaudited	Audited	Unaudited	Audited
I	<b>Income</b>				
	(a) Revenue from operations	186.73	202.82	179.95	777.56
	(b) Other income	1.18	0.59	1.57	4.01
	<b>Total Income (net)</b>	<b>187.91</b>	<b>203.41</b>	<b>181.52</b>	<b>781.57</b>
II	<b>Expenses</b>				
	(a) Cost of materials consumed	128.38	164.17	101.77	506.08
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(26.63)	(56.67)	(5.39)	(83.02)
	(c) Employee benefits expense	19.57	18.31	16.01	64.84
	(d) Finance costs	12.67	12.50	9.82	48.50
	(e) Depreciation and Amortization Expense	5.78	6.76	6.81	27.79
	(f) Other Expenses	33.90	40.63	36.76	153.34
	<b>Total Expenses</b>	<b>173.67</b>	<b>185.70</b>	<b>165.78</b>	<b>717.53</b>
III	Share of profit of associates	0.05	0.05	0.02	0.20
IV	<b>Profit/(loss) before exceptionals item and taxes (I - II + III)</b>	<b>14.29</b>	<b>17.76</b>	<b>15.76</b>	<b>64.24</b>
V	Exceptional items (Refer Note 4)	-	14.08	-	14.08
VI	<b>Profit/(loss) before tax (IV-V)</b>	<b>14.29</b>	<b>3.68</b>	<b>15.76</b>	<b>50.16</b>
VII	<b>Income Tax</b>				
	1. Prior year tax adjustment	-	0.16	-	0.62
	2. Current Tax	4.86	7.12	3.63	19.92
	3. Deferred Tax	(0.83)	(6.01)	0.66	(5.21)
VIII	<b>Profit for the period (VI-VII)</b>	<b>10.26</b>	<b>2.41</b>	<b>11.47</b>	<b>34.83</b>
IX	<b>Other comprehensive income</b>				
	i) Items that will not be reclassified to profit or loss	(0.14)	(0.09)	(0.18)	(0.56)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.03	0.00	0.05	0.12
	<b>Total Other comprehensive (expense)/ income, net of tax</b>	<b>(0.11)</b>	<b>(0.09)</b>	<b>(0.13)</b>	<b>(0.44)</b>
X	<b>Total comprehensive income for the period (VIII+IX)</b>	<b>10.15</b>	<b>2.32</b>	<b>11.34</b>	<b>34.39</b>
XI	Paid up equity Share Capital (Face Value per share of Rs. 10 each)	26.38	26.38	26.38	26.38
XII	Other Equity				763.01
XIII	Earning Per Equity Share Rs.				
	(a) Basic & Diluted (*Not Annualized)	3.89*	0.91*	4.35*	13.20

Place : Thane , India  
Date : August 02, 2025



For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Dr. Harin Kanani  
Managing Director  
DIN : 05136947

## Notes:

1. The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2025 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended and are in compliance with the presentation and disclosure requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and the other accounting principles generally accepted in India and were reviewed by the Statutory Auditor and recommended by the Audit Committee in its meeting held on August 2, 2025 and was approved by the Board of Directors at their meeting held on August 02, 2025.
2. The Hon'ble National Company Law Tribunal, Mumbai Bench ("Hon'ble NCLT") has on January 9, 2025, pronounced the order sanctioning and approving the Scheme of Amalgamation of Buli Chemicals India Private Limited i.e. wholly owned subsidiary ("**Transferor Company/BULI**") with Neogen Chemical Limited i.e. holding company ("**Transferee Company/ NCL/ the Company**") and their respective shareholders ("**Scheme**"), under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules framed thereunder ("**Act**") ("**Order**") with appointed date as April 1, 2024. The Scheme is effective from the date of filing of the certified copy of Order with the Registrar of Companies, Mumbai by both the Transferor Company and Transferee Company i.e. January 31, 2025 ("**Effective Date**").
3. The unaudited financial results of Dhara Fine chem Industries (a joint venture where the Company is holding 90% of the capital contribution), the wholly owned subsidiaries of the Company namely Neogen Ionics Limited and Neogen Chemicals Japan Corporation Limited for the quarter ended June 30, 2025 are considered for unaudited Consolidated Financial Results.
4. On March 05, 2025 there was fire at Multi-Purpose Plant (MPP3)- Facility, Tank Farms and warehouse at Dahej SEZ Plant of the Group. This incident led to damage of certain property, plant and equipment, inventory and interrupted business. The Group is adequately insured for reinstatement value of damaged fixed assets, inventory and loss of profits due to business interruption. The Group has intimated the fire incident with the insurance company and submitted loss estimate pertaining to replacement value of the damaged property, plant and equipment, loss of damaged inventory and incidental expenses incurred on account of fire. The Claim is admitted by the insurance company.

During the financial year and quarter ended March 2025, the Group has recognised loss of Rs 362.90 Crores on account of damage to certain property, plant & equipment, inventory and estimated cost of incidental charges. The Group has recognised insurance claim receivable of Rs 348.82 Crores to the extent of recovery of loss after adjusting applicable deductibility considering its assessment of loss and admissibility of claims as per the policy, adequacy of coverage and nature of loss and based upon the independent opinion obtained by the company from Independent Surveyor and Independent Expert Practitioner. The Group has not accounted claim for loss of profit due to business interruption and excess value of reinstatement of assets over written down value as per accounting conservatism. The aforementioned losses and corresponding insurance claim has been presented on a net basis of Rs 14.08 Cr under exceptional item in these Consolidated financial results for the previous quarter and year ended March 31, 2025

During the quarter ended 30 June 2025, Group has received Rs 50.55 Crores (including Rs 50 Crores as on account payment from insurance company).

Subsequent to the quarter ended 30 June 2025, the Company has received additional Rs 30 Crores as on account payment from Insurance company, accordingly net claim receivable as on date reduced to Rs 268.27 Crores.

On April 1, 2025, the Nomination and Remuneration Committee (NRC) of the Company has approved grant of 6,400 Employee Stock Options (ESOPs) to the total of 41 eligible employees of the Group, in India or outside



India, under Neogen Chemicals Limited Employees Stock Option Scheme 2024 ("Tranche – I Grant") at an Exercise Price for the Tranche - I Grant of Options shall be Rs. 1,389/- per Option (being granted at a discount of 10% of the Market Price (rounded off) i.e. closing price of previous trading day from grant day) as approved by the NRC of the Company. For more details visit:

<https://neogenchem.com/wp-content/uploads/NRCOutcome.pdf>

6. The Board of Directors of the Company had in its meeting held on March 25, 2025 approved Investment in Neogen Chemicals Japan Corporation Limited ("NCL Japan")- Wholly Owned Subsidiary of the Neogen Chemicals Limited (NCL) upto an amount of JPY 2,00,00,000 by way subscribing to the equity shares as may be issued, offered and allotted by NCL Japan constituting 100% shareholding in NCL Japan and accordingly the NCL has invested an amount of JPY 2,00,00,000 (equivalent INR 1,19,38,000) in NCL Japan. Further details in this respect can be accessed at:

<https://neogenchem.com/wp-content/uploads/BMoutcome.pdf> ,

[https://neogenchem.com/wp-content/uploads/update\\_ncljapan.pdf](https://neogenchem.com/wp-content/uploads/update_ncljapan.pdf) and

<https://neogenchem.com/wp-content/uploads/Update on Japan Investment01072025.pdf> .

7. The Board of Directors of Neogen Ionics Limited ("NIL") had in its meeting held on May 17, 2025, approved incorporation of NIL's Wholly Owned Subsidiary ("WOS") with the name Neogen Morita New Materials Limited ("NMNML"), which was incorporated on July 30, 2025. Accordingly, NMNML is a step down subsidiary of the "Neogen Chemicals Limited". For more details visit:

[https://neogenchem.com/wp-content/uploads/Reg\\_30\\_Incorporation\\_of\\_NMNML\\_clean.pdf](https://neogenchem.com/wp-content/uploads/Reg_30_Incorporation_of_NMNML_clean.pdf)

8. The Board of Directors of the Company has in its meeting held on July 12, 2025 approved the raising of funds upto Rs. 200 crores (Rupees Two hundred crores only) by issuance of fully paid, secured, listed, rated, redeemable, rupee denominated, non-cumulative, non-convertible debentures, in one or more tranches, on private placement basis. For more details visit:

<https://neogenchem.com/wp-content/uploads/outcome-bm-july-2025.pdf> .

9. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable with the current period's classification.
10. The figures for the quarter ended March 31, 2025 is arrived at as difference between the audited figures in respect of the full financial year and the unaudited figures up to nine months period ended December 31, 2024 which were subjected to limited review.
11. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.

Place : Thane , India  
Date : August 02,2025



For and on behalf of the Board of Directors of  
Neogen Chemicals Limited

Dr. Harin Kanani  
Managing Director  
DIN : 05136947



## Annexure 2

**Disclosure pursuant to Regulation 30 of the Listing Regulations read with SEBI Circulars with respect to retirement from and relinquishment of the position of Chairman and Managing Director by Mr. Haridas Kanani, and his appointment as Chairman Emeritus.**

Sr. No.	Particulars	Information of such event
1	Name of Key Managerial Personnel	Mr. Haridas Kanani
2	Designation	Chairman and Managing Director (till September 30, 2025) (Chairman Emeritus w.e.f. October 1, 2025)
3	Reason of change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Approval of the request of Mr. Haridas Kanani seeking retirement from and relinquishment of the position of Chairman and Managing Director with effect from end of working hours of September 30, 2025 and the Board also appreciated the huge contribution made by Mr. Haridas Kanani since the foundation of Neogen and the leadership provided by him in making Neogen a leading company in the area of Specialty Chemicals. Considering this huge contribution and the pivotal role played by him in establishing Company's strong foundation, driving sustained growth, and fostering a culture of excellence, integrity, and innovation, and in recognition of his visionary leadership, dedication, and outstanding contributions to the Company's progress, the Board has requested and recommended Mr. Haridas Kanani to continue in providing his guidance and mentorship to the Company and be conferred with the honorary title of "Chairman Emeritus" post his retirement w.e.f. October 1, 2025. The same was accepted by Mr. Haridas Kanani. The Board approved the conferring of the title Chairman Emeritus to Mr. Haridas Kanani w. e. f. October 1, 2025.
4	Date of Appointment/ cessation (as applicable)	Date of cessation as Chairman and Managing Director: October 1, 2025. Date of conferring the position of Chairman Emeritus: October 1, 2025.
5	Term of Appointment	Mr. Haridas Kanani with the honorary title of " <b>Chairman Emeritus</b> " w.e.f. October 1, 2025. He would cease to be a Managing Director and Chairman of the Company.
6	Brief Profile	Mr. Haridas Kanani is the Chairman and Managing Director of the Company and founder of the Company. He oversees manufacturing, research and development and process technology and general operation and management of the Company's manufacturing units. He holds a bachelor's degree in chemical engineering from the Indian Institute of Technology, Mumbai and is a member of Indian Institute of Chemical Engineers (MIICHE) since December, 1981. He has previously worked with Excel Industries Limited. He then founded Chem Ocean Industries which was set up as one of India's first Bromine plants using indigenous technology at Navalakhi, Gujarat. Due to floods in 1976, the Bromine plant was destroyed. He then set up Chem Ocean Consultants which provided consultancy, technology and engineering technologies to set up Bromine plants for other companies. In 1985 he set up Prachi Chemicals to manufacture organic and inorganic Bromides. Later in 1989 he established



		Neogen Chemicals Private Limited and has since served on the Board as Chairman and Managing Director.
7	Disclosure of relationships between Directors (in case of appointment of a Director)	Father of Dr. Harin Kanani, Managing Director of Neogen Chemicals Limited.
8	Shareholding in the Company, if any	61,53,887 Equity Shares of face value of Rs. 10 each
9	Information as required under Circular No. LIST/COMP/14/2018-19 and SE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Haridas Kanani is not debarred from holding the office of Director / Chairman Emeritus on account of any order of SEBI or any other such authority.

### **Annexure 3**

**Disclosure pursuant to Regulation 30 of the Listing Regulations read with SEBI Circulars with respect to issuance of Corporate Guarantee:**

<b>SR. NO.</b>	<b>PARTICULARS</b>	<b>Details w.r.t. Corporate Guarantee</b>
1	Name of party for which such guarantees or indemnity or surety was given.	Neogen Ionics Limited- Wholly owned Subsidiary of the Company (" <b>WOS- NIL</b> ")
2	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length"?	The transaction will fall under the related party transaction between holding company and its WOS-NIL and accordingly the holding company i.e. Neogen Chemicals Limited (" <b>the Company</b> ") is interested in the said transaction, to the extent of its shareholding and the directors being common on the Board of the Company and WOS-NIL are deemed to be interested in the said transaction.  The corporate guarantee will be provided by the Company on an arm's length basis, in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations.
3	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee.	The Company may issue a corporate guarantee in favour of Lenders to secure the Loan Facility that may be availed by WOS-NIL up to an additional limit of Rs. 125 Crores, over and above the existing limit of Rs. 1,250 crores, in one or more tranches.
4	Impact of such guarantees or indemnity or surety on listed entity.	The corporate guarantee provided is a contingent liability for the Company. This guarantee has been provided on behalf of a 100% wholly owned subsidiary of the Company which is part of the consolidated group. At this point, there is no impact of this guarantee on the Company.



#### Annexure 4

#### **Re- Appointment of Mr. Shyamsunder Upadhyay (DIN No. 07274873), as a Whole Time Director and a whole time Key Managerial Personnel (KMP) of Neogen Chemicals Limited**

Sr. No.	Particulars	Information of such event
1	Name of Key Managerial Personnel	Mr. Shyamsunder Upadhyay
2	Designation	Whole Time Director
3	Reason of change viz. appointment, re-appointment, resignation, removal, death or otherwise	Based on the recommendation of the Nomination and Remuneration Committee and subject to approval of the Members at the ensuing Annual General Meeting by way of Special Resolution under First Proviso of Section 196 (3) (a), the Board of Directors of the Company at its Meeting held today i.e. August 2, 2025, inter alia considered and approved Re-appointment of Mr. Shyamsunder Upadhyay (DIN: 07274873) as a Whole Time Director for a further term of 3 (Three) consecutive years commencing from October 1, 2025 to September 30, 2028 (both days inclusive), liable to retire by rotation, as per the provisions of section 203 of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations; inclusive).
4	Date of Re-Appointment/ cessation (as applicable)	Board Resolution: August 2, 2025 - w. e. f. October 1, 2025
5	Term of Appointment	Re-appointment of Mr. Shyamsunder Upadhyay (DIN: 07274873) as a Whole Time Director for a further term of 3 consecutive years commencing from October 1, 2025 to September 30, 2028 (both days inclusive), liable to retire by rotation, as per the provisions of section 203 of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations; inclusive) on the same terms and conditions.
6	Brief Profile	Mr. Shyamsunder Upadhyay oversees manufacturing, maintenance, projects, logistics, plant administration and engineering store in the Company. He has a master's degree in science from Vikram University, Ujjain. He has over 46 years of work experience in the field of chemicals and has previously been associated with companies, such as, Savita Chemicals, Wimco, Gharda Chemicals, Clariant India, Tytan Organics Limited, Arch Pharmalabs Limited and Laxmi Organic Industries Limited. Mr. Shyamsunder Upadhyay is Executive Director of Neogen Ionics Limited (the Wholly owned subsidiary of the Company), and Executive Director of Neogen Morita New Materials Limited (the Step Down Subsidiary of the Company)
7	Disclosure of relationships between Directors (in case of appointment of a Director)	Mr. Shyamsunder Upadhyay is not inter-se related to any other Director of the Company.
8	Shareholding in the Company, if any	80 Equity Shares of face value of Rs. 10 each
9	Information as required under Circular No. LIST/COMP/14/2018-19 and SE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Shyamsunder Upadhyay is not debarred from holding the office of director / whole time Director on account of any order of SEBI or any other such authority.

### Annexure 5

#### **Designation of Mr. Anurag Surana, the existing Non-Executive and Non-Independent Director as a Chairman and Non-Executive and Non-Independent Director**

Sr. No.	Details of events that need to be provided	Information of such event
1	Name of Director/Key Managerial Personnel	Mr. Anurag Surana (DIN: 00006665)
2	Designation	Non-Executive Non-Independent Director
3	Reason of change viz. appointment, resignation, removal, death or otherwise	Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at its Meeting held today i.e. August 2, 2025 inter alia considered and approved the designation of Mr. Anurag Surana (DIN No.: 00006665), existing Non-Executive and Non-Independent Director as a Chairman and Non-Executive and Non-Independent Director with effect from October 1, 2025, of the Company, liable to retire by rotation;
4	Date of Appointment/ cessation (as applicable)	Designation of Mr. Anurag Surana (DIN No.: 00006665) as an Chairman and Non-Executive and Non-Independent Director with effect from October 1, 2025, of the Company, liable to retire by rotation.
5	Term of Appointment	Designation of Mr. Anurag Surana (DIN No.: 00006665) as an Chairman and Non-Executive and Non-Independent Director with effect from October 1, 2025, of the Company, liable to retire by rotation
6	Brief Profile	Mr. Anurag Surana is a Chairman and Non-Executive Non-Independent Director of the Company. He has over 27 years' experience in the Specialty Chemical industry and is a known and reputed name in the chemical industry. He has a bachelor's degree in commerce with Honours from the University of Delhi. He founded and manages a consulting company Kagashin Global Network Private Limited, specialising in consulting with companies in the Specialty chemicals & agrochemical companies in India and abroad. He was earlier an executive director on the Board of PI Industries Limited. Mr. Surana is also on the board of other chemical companies like Privi Specialty Chemicals Ltd, Yasho Industries Limited Neogen Ionics Limited and Neogen Morita New Materials Limited.
7	Disclosure of relationships between Directors (in case of appointment of a Director)	Mr. Anurag Surana is not inter-se related to any other Director of the Company.
8	Shareholding, in any in the Company	2,25,000 Equity Shares.
9	Information as required under Circular No. LIST/COMP/14/2018-19 and SE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	We confirm that Mr. Anurag Surana has not been debarred from holding office of Director / Chairman by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority.

### Annexure 6

#### **Recommendation of appointment of Mr. Triplicane Commandoor Narasimhan Sai Krishnan (DIN No. 10498119), as an Executive Director of Neogen Chemicals Limited**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information of such event</b>
1	Name of Key Managerial Personnel	Mr. Triplicane Commandoor Narasimhan Sai Krishnan
2	Designation	Executive Director
3	Reason of change viz. appointment, re-appointment, resignation, removal, death or otherwise.	Based on the recommendation of the Nomination and Remuneration Committee and subject to approval of the Members at the ensuing Annual General Meeting, the Board of Directors of the Company at its Meeting held today i.e. August 2, 2025, inter alia considered and approved recommendation of appointment of Mr. <b>Triplicane Commandoor Narasimhan Sai Krishnan</b> as Executive Director of the Company for a term of 5 consecutive years commencing from October 1, 2025, to September 30, 2030 (both days inclusive), liable to retire by rotation, pursuant to Section 152(2) of the Companies Act, 2013, and other applicable provisions of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations.
4	Date of Appointment/ cessation (asw. e. f. October 1, 2025 applicable)	
5	Term of Appointment	Appointment of Mr. Triplicane Commandoor Narasimhan Saikrishnan (DIN: 10498119) as an Executive Director of the Company for a term of 5 consecutive years commencing from October 1, 2025, to September 30, 2030 (both days inclusive), liable to retire by rotation, pursuant to applicable provisions of the Companies Act, 2013 read with applicable rules and applicable provisions of Listing Regulations.
6	Brief Profile	Mr. Triplicane Commandoor Narasimhan Sai Krishnan oversees operations in the Company. He Holds MBA degree with Chemical engineering. He has over 33 years of work experience in the field of Manufacturing, Projects, Procurement & Supply Chain with specialty chemicals, petrochemicals, paints, inks & FMCG industries. He is the Executive Director of Neogen Ionics Limited (the Wholly owned subsidiary of the Company), and Executive Director of Neogen Morita New Materials Limited (the Step Down Subsidiary of the Company).
7	Disclosure of relationships between Directors (in case of appointment of a Director)	Mr. Triplicane Commandoor Narasimhan Sai Krishnan is not inter-related to any other Director of the Company.
8	Shareholding in the Company, if any.	300 Equity Shares of face value of Rs. 10 each

9	Information as required under Circular No. LIST/COMP/14/2018-19 and SE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Triplicane Commandoor Narasimhan Sai Krishnan is not debarred from holding the office of director on account of any order of SEBI or any other such authority.
---	--	--

**For Neogen Chemicals Limited**

**Unnati Kanani**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 35131**

**Place:** Thane  
**Date:** August 2, 2025